| Year |
Citation |
Score |
| 2023 |
Kim J, Song J, Kambari Y, Plitman E, Shah P, Iwata Y, Caravaggio F, Brown EE, Nakajima S, Chakravarty MM, De Luca V, Remington G, Graff-Guerrero A, Gerretsen P. Cortical thinning in relation to impaired insight into illness in patients with treatment resistant schizophrenia. Schizophrenia (Heidelberg, Germany). 9: 27. PMID 37120642 DOI: 10.1038/s41537-023-00347-y |
0.31 |
|
| 2023 |
Honda S, Matsushita K, Noda Y, Tarumi R, Nomiyama N, Tsugawa S, Nakajima S, Mimura M, Fujii S. Music rhythm perception and production relate to treatment response in schizophrenia. Schizophrenia Research. 252: 69-76. PMID 36634450 DOI: 10.1016/j.schres.2022.12.040 |
0.305 |
|
| 2020 |
Wada M, Nakajima S, Tarumi R, Masuda F, Miyazaki T, Tsugawa S, Ogyu K, Honda S, Matsushita K, Kikuchi Y, Fujii S, Blumberger DM, Daskalakis ZJ, Mimura M, Noda Y. Resting-State Isolated Effective Connectivity of the Cingulate Cortex as a Neurophysiological Biomarker in Patients with Severe Treatment-Resistant Schizophrenia. Journal of Personalized Medicine. 10. PMID 32823914 DOI: 10.3390/Jpm10030089 |
0.339 |
|
| 2020 |
Kubota M, Moriguchi S, Takahata K, Nakajima S, Horita N. Treatment effects on neurometabolite levels in schizophrenia: A meta-analysis dataset of proton magnetic resonance spectroscopy. Data in Brief. 31: 105862. PMID 32637482 DOI: 10.1016/J.Dib.2020.105862 |
0.376 |
|
| 2020 |
Kubota M, Moriguchi S, Takahata K, Nakajima S, Horita N. Treatment effects on neurometabolite levels in schizophrenia: A systematic review and meta-analysis of proton magnetic resonance spectroscopy studies. Schizophrenia Research. PMID 32505446 DOI: 10.1016/J.Schres.2020.03.069 |
0.393 |
|
| 2020 |
Takahashi T, Tsugawa S, Nakajima S, Plitman E, Chakravarty MM, Masuda F, Wada M, Kurose S, Ochi R, Matsushita K, Sasabayashi D, Nakamura M, Nishikawa Y, Takayanagi Y, Nishiyama S, et al. Thalamic and striato-pallidal volumes in schizophrenia patients and individuals at risk for psychosis: A multi-atlas segmentation study. Schizophrenia Research. PMID 32448678 DOI: 10.1016/J.Schres.2020.04.016 |
0.414 |
|
| 2020 |
Shah P, Plitman E, Iwata Y, Kim J, Nakajima S, Chan N, Brown EE, Caravaggio F, Torres E, Hahn M, Chakravarty MM, Remington G, Gerretsen P, Graff-Guerrero A. Glutamatergic neurometabolites and cortical thickness in treatment-resistant schizophrenia: Implications for glutamate-mediated excitotoxicity. Journal of Psychiatric Research. 124: 151-158. PMID 32169688 DOI: 10.1016/J.Jpsychires.2020.02.032 |
0.395 |
|
| 2020 |
Nagata T, Shinagawa S, Yoshida K, Noda Y, Shigeta M, Mimura M, Nakajima S. Early Improvements of Individual Symptoms With Antipsychotics Predict Subsequent Treatment Response of Neuropsychiatric Symptoms in Alzheimer's Disease: A Re-Analysis of the CATIE-AD Study The Journal of Clinical Psychiatry. 81: 0-0. PMID 32074412 DOI: 10.4088/Jcp.19M12961 |
0.355 |
|
| 2020 |
Ochi R, Noda Y, Tsuchimoto S, Tarumi R, Honda S, Matsushita K, Tsugawa S, Plitman E, Masuda F, Ogyu K, Wada M, Miyazaki T, Fujii S, Chakravarty MM, Graff-Guerrero A, ... ... Nakajima S, et al. White matter microstructural organizations in patients with severe treatment-resistant schizophrenia: A diffusion tensor imaging study. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 100: 109871. PMID 31962187 DOI: 10.1016/J.Pnpbp.2020.109871 |
0.357 |
|
| 2020 |
Ogyu K, Honda S, Matsushita K, Noda Y, Kato H, Kusudo K, Kim J, Plitman E, Koizumi T, Koreki A, Fujii S, Chakravarty MM, Uchida H, Graff-Guerrero A, Onaya M, ... ... Nakajima S, et al. M23. Alteration Of Regional Cerebral Blood Flow Measured By Arterial Spin Labeling In Patients With Treatment-Resistant Schizophrenia Schizophrenia Bulletin. 46. DOI: 10.1093/Schbul/Sbaa030.335 |
0.307 |
|
| 2020 |
Tarumi R, Tsugawa S, Noda Y, Plitman E, Honda S, Matshusita K, Chavez S, Sawada K, Wada M, Matsui M, Fujii S, Miyazaki T, Chakravarty M, Uchida H, Remington G, ... ... Nakajima S, et al. T212. Levels Of Glutamatergic Neurometabolites In Patients With Severe Treatment-Resistant Schizophrenia: A Proton Magnetic Resonance Spectroscopy Study Schizophrenia Bulletin. 46. DOI: 10.1093/Schbul/Sbaa029.772 |
0.348 |
|
| 2020 |
Uchida H, Miyazaki T, Nakajima W, Hatano M, Tani H, Nagai N, Koizumi T, Nakajima S, Mimura M, Takahashi T. T166. Visualization Of Ampa Receptors In Patients With Schizophrenia And Depression: The First Pet Imaging Study Schizophrenia Bulletin. 46. DOI: 10.1093/Schbul/Sbaa029.726 |
0.349 |
|
| 2020 |
Plitman E, Ochi R, Patel R, Tsugawa S, Tarumi R, Honda S, Matsushita K, Fujii S, Uchida H, Mimura M, Noda Y, Devenyi GA, Nakajima S, Chakravarty M. Using Non-Negative Matrix Factorization to Examine Treatment Resistance and Response in Patients With Schizophrenia: A Multimodal Imaging Study Biological Psychiatry. 87: S350. DOI: 10.1016/J.Biopsych.2020.02.899 |
0.362 |
|
| 2019 |
Kim J, Plitman E, Iwata Y, Nakajima S, Mar W, Patel R, Chavez S, Chung JK, Caravaggio F, Chakravarty MM, Remington G, Gerretsen P, Graff-Guerrero A. Neuroanatomical profiles of treatment-resistance in patients with schizophrenia spectrum disorders. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 109839. PMID 31843627 DOI: 10.1016/J.Pnpbp.2019.109839 |
0.395 |
|
| 2019 |
Tarumi R, Tsugawa S, Noda Y, Plitman E, Honda S, Matsushita K, Chavez S, Sawada K, Wada M, Matsui M, Fujii S, Miyazaki T, Chakravarty MM, Uchida H, Remington G, ... ... Nakajima S, et al. Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 31842203 DOI: 10.1038/S41386-019-0589-Z |
0.401 |
|
| 2019 |
Shah P, Iwata Y, Brown EE, Kim J, Sanches M, Takeuchi H, Nakajima S, Hahn M, Remington G, Gerretsen P, Graff-Guerrero A. Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study. European Archives of Psychiatry and Clinical Neuroscience. PMID 31428862 DOI: 10.1007/S00406-019-01053-6 |
0.372 |
|
| 2019 |
Kim J, Plitman E, Nakajima S, Alshehri Y, Iwata Y, Chung JK, Caravaggio F, Menon M, Blumberger DM, Pollock BG, Remington G, De Luca V, Graff-Guerrero A, Gerretsen P. Modulation of brain activity with transcranial direct current stimulation: Targeting regions implicated in impaired illness awareness in schizophrenia. European Psychiatry : the Journal of the Association of European Psychiatrists. 61: 63-71. PMID 31326732 DOI: 10.1016/J.Eurpsy.2019.06.007 |
0.347 |
|
| 2019 |
Kim J, Ozzoude M, Nakajima S, Shah P, Caravaggio F, Iwata Y, De Luca V, Graff-Guerrero A, Gerretsen P. Insight and medication adherence in schizophrenia: An analysis of the CATIE data. Neuropharmacology. PMID 31077729 DOI: 10.1016/J.Neuropharm.2019.05.011 |
0.367 |
|
| 2019 |
Tsugawa S, Noda Y, Tarumi R, Mimura Y, Yoshida K, Iwata Y, Elsalhy M, Kuromiya M, Kurose S, Masuda F, Morita S, Ogyu K, Plitman E, Wada M, Miyazaki T, ... ... Nakajima S, et al. Glutathione levels and activities of glutathione metabolism enzymes in patients with schizophrenia: A systematic review and meta-analysis. Journal of Psychopharmacology (Oxford, England). 269881119845820. PMID 31039654 DOI: 10.1177/0269881119845820 |
0.358 |
|
| 2019 |
Funaki K, Nakajima S, Noda Y, Wake T, Ito D, Yamagata B, Yoshizaki T, Kameyama M, Nakahara T, Murakami K, Jinzaki M, Mimura M, Tabuchi H. Can we predict amyloid deposition by objective cognition and regional cerebral blood flow in patients with subjective cognitive decline? Psychogeriatrics : the Official Journal of the Japanese Psychogeriatric Society. PMID 30688000 DOI: 10.1111/Psyg.12397 |
0.312 |
|
| 2019 |
Shah P, Iwata Y, Brown E, Caravaggio F, Kim J, Sanches M, Takeuchi H, Nakajima S, Hahn M, Remington G, Gerretsen P, Graff-Guerrero A. S185. Treatment Response Trajectories in Treatment-Resistant Schizophrenia: A Chart Review Study Biological Psychiatry. 85. DOI: 10.1016/J.Biopsych.2019.03.936 |
0.352 |
|
| 2019 |
Carmona ET, Iwata Y, Nakajima S, Plitman E, Caravaggio F, Brown E, Kim J, Shah P, Mar W, Chavez S, Remington G, Gerretsen P, Graff-Guerrero A. S167. Increased N-Acetylaspartate and Myo-Inositol Levels in Clozapine-Responders and Clozapine-Resistant Patients With Schizophrenia Biological Psychiatry. 85. DOI: 10.1016/J.Biopsych.2019.03.918 |
0.373 |
|
| 2019 |
Plitman E, Bedford S, Fuente-Sandoval Cdl, Graff-Guerrero A, Iwata Y, Nakajima S, Noda Y, Tarumi R, Tsugawa S, Devenyi GA, Near J, Chakravarty M. T199. Assessing Neurometabolite Alterations in the Anterior Cingulate Cortex of Patients With Schizophrenia: A Multi-Site Proton Magnetic Resonance Spectroscopy Initiative Biological Psychiatry. 85: S207. DOI: 10.1016/J.Biopsych.2019.03.522 |
0.324 |
|
| 2018 |
Nagata T, Shinagawa S, Nakajima S, Mimura M, Shigeta M. Association between Neuropsychiatric Improvement and Neurocognitive Change in Alzheimer's Disease: Analysis of the CATIE-AD Study. Journal of Alzheimer's Disease. 66: 139-148. PMID 30248052 DOI: 10.3233/Jad-180304 |
0.309 |
|
| 2018 |
Ozzoude M, Nakajima S, Plitman E, Chung JK, Kim J, Iwata Y, Caravaggio F, Takeuchi H, Uchida H, Graff-Guerrero A, Gerretsen P. The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotics trials of intervention effectiveness (CATIE) data. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 30172739 DOI: 10.1016/J.Pnpbp.2018.08.033 |
0.4 |
|
| 2018 |
Sanada K, de Azúa SR, Nakajima S, Alberich S, Ugarte A, Zugasti J, Vega P, Martínez-Cengotitabengoa M, González-Pinto A. Correlates of neurocognitive functions in individuals at ultra-high risk for psychosis - A 6-month follow-up study. Psychiatry Research. 268: 1-7. PMID 29986171 DOI: 10.1016/J.Psychres.2018.06.053 |
0.301 |
|
| 2018 |
Iwata Y, Nakajima S, Plitman E, Mihashi Y, Caravaggio F, Chung JK, Kim J, Gerretsen P, Mimura M, Remington G, Graff-Guerrero A. Neurometabolite levels in antipsychotic-naïve/free patients with schizophrenia: A systematic review and meta-analysis ofH-MRS studies. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 29580804 DOI: 10.1016/J.Pnpbp.2018.03.016 |
0.389 |
|
| 2018 |
Plitman E, Chavez S, Nakajima S, Iwata Y, Chung JK, Caravaggio F, Kim J, Alshehri Y, Chakravarty MM, De Luca V, Remington G, Gerretsen P, Graff-Guerrero A. Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study. Psychiatry Research. 273: 16-24. PMID 29414127 DOI: 10.1016/J.Pscychresns.2018.01.004 |
0.38 |
|
| 2018 |
Caravaggio F, Fervaha G, Iwata Y, Plitman E, Chung JK, Nakajima S, Mar W, Gerretsen P, Kim J, Chakravarty M, Mulsant B, Pollock B, Mamo D, Remington G, Graff-Guerrero A. S175. Amotivation Is Associated With Smaller Ventral Striatum Volumes In Older Patients With Schizophrenia. Schizophrenia Bulletin. 44. DOI: 10.1093/Schbul/Sby018.962 |
0.382 |
|
| 2018 |
Iwata Y, Nakajima S, Plitman E, Chung JK, Caravaggio F, Kim J, Brown E, Chan N, Shah P, Chavez S, Gerretsen P, Mimura M, Remington G, Graff-Guerrero A. S16. GLUTAMATERGIC NEUROMETABOLITE LEVELS IN PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA: A CROSS-SECTIONAL 3T PROTON MRS STUDY Schizophrenia Bulletin. 44: S329-S329. DOI: 10.1093/Schbul/Sby018.803 |
0.348 |
|
| 2018 |
Plitman E, Iwata Y, Nakajima S, Chung JK, Patel R, Caravaggio F, Kim J, De Luca V, Chavez S, Remington G, Mallar Chakravarty M, Gerretsen P, Graff-Guerrero A. F178. NEUROANATOMICAL PROFILES OF TREATMENT-RESISTANCE IN PATIENTS WITH SCHIZOPHRENIA Schizophrenia Bulletin. 44: S290-S290. DOI: 10.1093/Schbul/Sby017.709 |
0.362 |
|
| 2018 |
Iwata Y, Nakajima S, Plitman E, Chung JK, Caravaggio F, Kim J, Brown E, Shah P, Chan N, Gerretsen P, Mimura M, Chavez S, Remington G, Graff-Guerrero A. F230. Glutamatergic Neurometabolite Levels in Patients With Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton MRS Study Biological Psychiatry. 83. DOI: 10.1016/J.Biopsych.2018.02.844 |
0.34 |
|
| 2017 |
Caravaggio F, Fervaha G, Iwata Y, Plitman E, Chung JK, Nakajima S, Mar W, Gerretsen P, Kim J, Chakravarty MM, Mulsant B, Pollock B, Mamo D, Remington G, Graff-Guerrero A. Amotivation is associated with smaller ventral striatum volumes in older patients with schizophrenia. International Journal of Geriatric Psychiatry. PMID 29110353 DOI: 10.1002/Gps.4818 |
0.408 |
|
| 2017 |
Gerretsen P, Chung JK, Shah P, Plitman E, Iwata Y, Caravaggio F, Nakajima S, Pollock BG, Graff-Guerrero A. Anosognosia Is an Independent Predictor of Conversion From Mild Cognitive Impairment to Alzheimer's Disease and Is Associated With Reduced Brain Metabolism. The Journal of Clinical Psychiatry. PMID 29022655 DOI: 10.4088/Jcp.16M11367 |
0.315 |
|
| 2017 |
Chung JK, Plitman E, Nakajima S, Caravaggio F, Shinagawa S, Iwata Y, Gerretsen P, Kim J, Takeuchi H, Patel R, Chakravarty MM, Strafella A, Graff-Guerrero A. The Effects of Cortical Hypometabolism and Hippocampal Atrophy on Clinical Trajectories in Mild Cognitive Impairment with Suspected Non-Alzheimer's Pathology: A Brief Report. Journal of Alzheimer's Disease : Jad. PMID 28826178 DOI: 10.3233/Jad-170098 |
0.326 |
|
| 2017 |
Nagata T, Nakajima S, Shinagawa S, Plitman E, Nakayama K, Graff-Guerrero A, Mimura M. Baseline Predictors of Antipsychotic Treatment Continuation and Response at Week 8 in Patients with Alzheimer's Disease with Psychosis or Aggressive Symptoms: An Analysis of the CATIE-AD Study. Journal of Alzheimer's Disease. 60: 263-272. PMID 28800334 DOI: 10.3233/Jad-170412 |
0.362 |
|
| 2017 |
Chung JK, Plitman E, Nakajima S, Caravaggio F, Iwata Y, Gerretsen P, Kim J, Takeuchi H, Shinagawa S, Patel R, Chakravarty MM, Graff-Guerrero A. Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer's Disease Pathology. Journal of Alzheimer's Disease : Jad. PMID 28505977 DOI: 10.3233/Jad-170201 |
0.318 |
|
| 2017 |
Caravaggio F, Gerretsen P, Mar W, Chung JK, Plitman E, Nakajima S, Kim J, Iwata Y, Patel R, Chakravarty MM, Remington G, Graff-Guerrero A, Menon M. Intranasal oxytocin does not modulate jumping to conclusions in schizophrenia: Potential interactions with caudate volume and baseline social functioning. Psychoneuroendocrinology. 81: 80-87. PMID 28431278 DOI: 10.1016/J.Psyneuen.2017.03.020 |
0.382 |
|
| 2017 |
Kim J, Plitman E, Nakajima S, Chung JK, Alshehri Y, Iwata Y, Caravaggio F, Pollock BG, Pothier D, Graff-Guerrero A, Gerretsen P. Impaired illness awareness and leftward visuospatial inattention in schizophrenia are attributable to a common neural deficit - Posterior parietal hemispheric imbalance. Medical Hypotheses. 100: 19-22. PMID 28236841 DOI: 10.1016/J.Mehy.2017.01.007 |
0.364 |
|
| 2017 |
Plitman E, Iwata Y, Caravaggio F, Nakajima S, Chung JK, Gerretsen P, Kim J, Takeuchi H, Chakravarty MM, Remington G, Graff-Guerrero A. Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis. Schizophrenia Bulletin. PMID 28187219 DOI: 10.1093/Schbul/Sbw221 |
0.399 |
|
| 2017 |
Nagata T, Nakajima S, Shinagawa S, Plitman E, Graff-Guerrero A, Mimura M, Nakayama K. Psychosocial or clinico-demographic factors related to neuropsychiatric symptoms in patients with Alzheimer's disease needing interventional treatment: analysis of the CATIE-AD study. International Journal of Geriatric Psychiatry. 32: 1264-1271. PMID 27714849 DOI: 10.1002/Gps.4607 |
0.326 |
|
| 2017 |
Iwata Y, Nakajima S, Plitman E, Mihashi Y, Caravaggio F, Chung JK, Kim J, Gerretsen P, Mimura M, Remington G, Graff-Guerrero A. SU84. Neurometabolite Levels in Antipsychotic Naive/Free Patients With Schizophrenia: A Meta-Analysis of 1H-MRS Studies. Schizophrenia Bulletin. 43. DOI: 10.1093/Schbul/Sbx024.080 |
0.39 |
|
| 2017 |
Kim J, Plitman E, Nakajima S, Chung JK, Alshehri Y, Iwata Y, Caravaggio F, Pollock B, Pothier D, Graff-Guerrero A, Gerretsen P. SU56. Impaired Illness Awareness and Leftward Visuospatial Inattention in Schizophrenia Are Attributable to a Common Neural Deficit—Posterior Parietal Hemispheric Imbalance Schizophrenia Bulletin. 43. DOI: 10.1093/Schbul/Sbx024.054 |
0.367 |
|
| 2017 |
Chung JK, Nakajima S, Plitman E, Caravaggio F, Gerretsen P, Iwata Y, Uy D, Chakravarty MM, Graff-Guerrero A. M5. Beta Amyloid Level is not Elevated in Elderly Patients With Schizophrenia: Are There Potential Neuroprotective Effects of Antipsychotics on Beta-Amyloid Pathology? Schizophrenia Bulletin. 43: S212-S212. DOI: 10.1093/Schbul/Sbx022.004 |
0.311 |
|
| 2017 |
Tani H, Suzuki T, Nakajima S, Koizumi T, Mimura M, Uchida H. AMPA receptors in schizophrenia: a systematic review of postmortem studies on receptor subunit expression and binding European Neuropsychopharmacology. 27. DOI: 10.1016/S0924-977X(17)31387-1 |
0.311 |
|
| 2017 |
Gerretsen P, Plitman E, Kim J, Chung J, Nakajima S, Alshehri Y, Caravaggio F, Iwata Y, Blumberger D, Pollock B, Graff-Guerrero A. 397. TDCS Modulates Brain Regions Associated with Impaired Illness Awareness in Schizophrenia Spectrum Disorders Biological Psychiatry. 81. DOI: 10.1016/J.Biopsych.2017.02.414 |
0.35 |
|
| 2016 |
Iwata Y, Nakajima S, Caravaggio F, Suzuki T, Uchida H, Plitman E, Chung JK, Mar W, Gerretsen P, Pollock BG, Mulsant BH, Rajji TK, Mamo DC, Graff-Guerrero A. Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia. The Journal of Clinical Psychiatry. 77: e1557-e1563. PMID 28086010 DOI: 10.4088/Jcp.15M10538 |
0.369 |
|
| 2016 |
Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, Bloomfield MA, Bressan RA, Buchanan RW, Carpenter WT, Castle DJ, Citrome L, Daskalakis ZJ, Davidson M, Drake RJ, ... ... Nakajima S, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. The American Journal of Psychiatry. appiajp201616050503. PMID 27919182 DOI: 10.1176/Appi.Ajp.2016.16050503 |
0.343 |
|
| 2016 |
Rajji TK, Mulsant BH, Nakajima S, Caravaggio F, Suzuki T, Uchida H, Gerretsen P, Mar W, Pollock BG, Mamo DC, Graff-Guerrero A. Cognition and Dopamine D2 Receptor Availability in the Striatum in Older Patients with Schizophrenia. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. PMID 27745822 DOI: 10.1016/J.Jagp.2016.08.001 |
0.397 |
|
| 2016 |
Fervaha G, Caravaggio F, Mamo DC, Mulsant BH, Pollock BG, Nakajima S, Gerretsen P, Rajji TK, Mar W, Iwata Y, Plitman E, Chung JK, Remington G, Graff-Guerrero A. Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study. Psychopharmacology. PMID 27557949 DOI: 10.1007/S00213-016-4415-6 |
0.378 |
|
| 2016 |
Chung JK, Nakajima S, Plitman E, Iwata Y, Uy D, Gerretsen P, Caravaggio F, Chakravarty MM, Graff-Guerrero A. Β-Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. PMID 27526990 DOI: 10.1016/J.Jagp.2016.03.013 |
0.374 |
|
| 2016 |
Nagata T, Shinagawa S, Nakajima S, Plitman E, Mihashi Y, Hayashi S, Mimura M, Nakayama K. Classification of Neuropsychiatric Symptoms Requiring Antipsychotic Treatment in Patients with Alzheimer's Disease: Analysis of the CATIE-AD Study. Journal of Alzheimer's Disease : Jad. PMID 26836181 DOI: 10.3233/Jad-150869 |
0.339 |
|
| 2016 |
Funaki K, Nakajima S, Suzuki T, Mimura M, Uchida H. Early Improvements in Individual Symptoms to Predict Later Remission in Major Depressive Disorder Treated with Mirtazapine. Journal of Clinical Pharmacology. PMID 26813241 DOI: 10.1002/Jcph.710 |
0.31 |
|
| 2015 |
Chung JK, Plitman E, Nakajima S, Chow TW, Chakravarty MM, Caravaggio F, Gerretsen P, Brown EE, Iwata Y, Mulsant BH, Graff-Guerrero A. Lifetime History of Depression Predicts Increased Amyloid-β Accumulation in Patients with Mild Cognitive Impairment. Journal of Alzheimer's Disease : Jad. 49: 1189-1190. PMID 26756327 DOI: 10.3233/Jad-159007 |
0.303 |
|
| 2015 |
Chung JK, Plitman E, Nakajima S, Chakravarty MM, Caravaggio F, Takeuchi H, Gerretsen P, Iwata Y, Patel R, Mulsant BH, Graff-Guerrero A. Depressive Symptoms and Small Hippocampal Volume Accelerate the Progression to Dementia from Mild Cognitive Impairment. Journal of Alzheimer's Disease : Jad. PMID 26519442 DOI: 10.3233/Jad-150679 |
0.342 |
|
| 2015 |
Chung JK, Plitman E, Nakajima S, Chakravarty MM, Caravaggio F, Gerretsen P, Iwata Y, Graff-Guerrero A. Cortical Amyloid β Deposition and Current Depressive Symptoms in Alzheimer Disease and Mild Cognitive Impairment. Journal of Geriatric Psychiatry and Neurology. PMID 26400248 DOI: 10.1177/0891988715606230 |
0.307 |
|
| 2015 |
Graff-Guerrero A, Rajji TK, Mulsant BH, Nakajima S, Caravaggio F, Suzuki T, Uchida H, Gerretsen P, Mar W, Pollock BG, Mamo DC. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study. Jama Psychiatry. 72: 927-34. PMID 26131622 DOI: 10.1001/Jamapsychiatry.2015.0891 |
0.375 |
|
| 2015 |
Caravaggio F, Hahn M, Nakajima S, Gerretsen P, Remington G, Graff-Guerrero A. Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia. Medical Hypotheses. PMID 26118462 DOI: 10.1016/J.Mehy.2015.06.011 |
0.354 |
|
| 2015 |
Iwata Y, Nakajima S, Suzuki T, Keefe RS, Plitman E, Chung JK, Caravaggio F, Mimura M, Graff-Guerrero A, Uchida H. Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials. Molecular Psychiatry. PMID 26077694 DOI: 10.1038/Mp.2015.68 |
0.375 |
|
| 2015 |
Nakajima S, Caravaggio F, Mamo DC, Mulsant BH, Chung JK, Plitman E, Iwata Y, Gerretsen P, Uchida H, Suzuki T, Mar W, Wilson AA, Houle S, Graff-Guerrero A. Dopamine D₂/₃ receptor availability in the striatum of antipsychotic-free older patients with schizophrenia-A [¹¹C]-raclopride PET study. Schizophrenia Research. 164: 263-7. PMID 25757713 DOI: 10.1016/J.Schres.2015.02.020 |
0.382 |
|
| 2015 |
Nakajima S, Takeuchi H, Plitman E, Fervaha G, Gerretsen P, Caravaggio F, Chung JK, Iwata Y, Remington G, Graff-Guerrero A. Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia. Schizophrenia Research. 164: 164-75. PMID 25684554 DOI: 10.1016/J.Schres.2015.01.043 |
0.379 |
|
| 2015 |
Chung JK, Plitman E, Nakajima S, Chow TW, Chakravarty MM, Caravaggio F, Gerretsen P, Brown EE, Iwata Y, Mulsant BH, Graff-Guerrero A. Lifetime History of Depression Predicts Increased Amyloid-β Accumulation in Patients with Mild Cognitive Impairment. Journal of Alzheimer's Disease : Jad. 45: 907-19. PMID 25633681 DOI: 10.3233/Jad-142931 |
0.334 |
|
| 2015 |
Nakajima S, Takeuchi H, Fervaha G, Plitman E, Chung JK, Caravaggio F, Iwata Y, Mihashi Y, Gerretsen P, Remington G, Mulsant B, Graff-Guerrero A. Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data. Schizophrenia Research. 161: 429-33. PMID 25556080 DOI: 10.1016/J.Schres.2014.12.024 |
0.384 |
|
| 2014 |
Plitman E, Nakajima S, de la Fuente-Sandoval C, Gerretsen P, Chakravarty MM, Kobylianskii J, Chung JK, Caravaggio F, Iwata Y, Remington G, Graff-Guerrero A. Glutamate-mediated excitotoxicity in schizophrenia: a review. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 1591-605. PMID 25159198 DOI: 10.1016/J.Euroneuro.2014.07.015 |
0.385 |
|
| 2014 |
Shinagawa S, Nakajima S, Plitman E, Graff-Guerrero A, Mimura M, Nakayama K, Miller BL. Psychosis in frontotemporal dementia. Journal of Alzheimer's Disease : Jad. 42: 485-99. PMID 24898651 DOI: 10.3233/Jad-140312 |
0.371 |
|
| 2014 |
Caravaggio F, Blumberger DM, Nakajima S, Mulsant BH, Graff-Guerrero A. Occupancy of Dopamine D3 Receptors by Aripiprazole in Treatment Resistant Late-Life Depressed Patients Depends on Length of Treatment as Evidenced by in vivo Imaging with [11C]-(+)-PHNO American Journal of Geriatric Psychiatry. 22. DOI: 10.1016/J.Jagp.2013.12.094 |
0.394 |
|
| 2013 |
Sakurai H, Uchida H, Abe T, Nakajima S, Suzuki T, Pollock BG, Sato Y, Mimura M. Trajectories of individual symptoms in remitters versus non-remitters with depression. Journal of Affective Disorders. 151: 506-13. PMID 23886402 DOI: 10.1016/J.Jad.2013.06.035 |
0.3 |
|
| 2013 |
Nakajima S, Gerretsen P, Takeuchi H, Caravaggio F, Chow T, Le Foll B, Mulsant B, Pollock B, Graff-Guerrero A. The potential role of dopamine D₃ receptor neurotransmission in cognition. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 23: 799-813. PMID 23791072 DOI: 10.1016/J.Euroneuro.2013.05.006 |
0.328 |
|
| 2013 |
Tanaka S, Nagase T, Suzuki T, Nomura K, Takeuchi H, Nakajima S, Uchida H, Yagi G, Watanabe K, Mimura M. Factor structure of the targeted inventory on problems in schizophrenia. Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology. 11: 18-23. PMID 23678350 DOI: 10.9758/Cpn.2013.11.1.18 |
0.304 |
|
| 2013 |
Nakajima S, Rajji T, Gerretsen P, Suzuki T, Caravaggio F, Mar W, Mulsant BH, Pollock BG, Mamo D, Graff-Guerrero A. Improvement in Attention after Antipsychotic Dose Reduction in Late-life Schizophrenia: A Pilot PET-Cognition Study American Journal of Geriatric Psychiatry. 21. DOI: 10.1016/J.Jagp.2012.12.163 |
0.367 |
|
| 2012 |
Tani H, Uchida H, Suzuki T, Shibuya Y, Shimanuki H, Watanabe K, Den R, Nishimoto M, Hirano J, Takeuchi H, Nio S, Nakajima S, Kitahata R, Tsuboi T, Tsunoda K, et al. Dental conditions in inpatients with schizophrenia: a large-scale multi-site survey. Bmc Oral Health. 12: 32. PMID 22901247 DOI: 10.1186/1472-6831-12-32 |
0.377 |
|
| 2011 |
Nakajima S, Uchida H, Suzuki T, Watanabe K, Hirano J, Yagihashi T, Takeuchi H, Abe T, Kashima H, Mimura M. Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: a randomized open-label trial. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 35: 1983-9. PMID 21889560 DOI: 10.1016/J.Pnpbp.2011.08.008 |
0.305 |
|
| 2011 |
Ishida T, Uchida H, Suzuki T, Nakajima S, Watanabe K, Kashima H. Plasma substance P level in patients with schizophrenia: a cross-sectional study. Psychiatry and Clinical Neurosciences. 65: 526-8. PMID 21851462 DOI: 10.1111/J.1440-1819.2011.02244.X |
0.357 |
|
| 2011 |
Tsutsumi C, Uchida H, Suzuki T, Watanabe K, Takeuchi H, Nakajima S, Kimura Y, Tsutsumi Y, Ishii K, Imasaka Y, Kapur S. The evolution of antipsychotic switch and polypharmacy in natural practice--a longitudinal perspective. Schizophrenia Research. 130: 40-6. PMID 21624824 DOI: 10.1016/J.Schres.2011.05.013 |
0.369 |
|
| 2011 |
Minamisawa A, Suzuki T, Watanabe K, Imasaka Y, Kimura Y, Takeuchi H, Nakajima S, Kashima H, Uchida H. Patient's trust in their psychiatrist: a cross-sectional survey. European Archives of Psychiatry and Clinical Neuroscience. 261: 603-8. PMID 21365359 DOI: 10.1007/S00406-011-0199-1 |
0.303 |
|
| 2011 |
Takeuchi H, Suzuki T, Uchida H, Kikuchi T, Nakajima S, Manki H, Watanabe K, Kashima H. How long to wait before reducing antipsychotic dosage in stabilized patients with schizophrenia? A retrospective chart review. Journal of Psychiatric Research. 45: 1083-8. PMID 21303712 DOI: 10.1016/J.Jpsychires.2011.01.007 |
0.379 |
|
| 2010 |
Suzuki T, Takeuchi H, Nakajima S, Nomura K, Uchida H, Yagi G, Watanabe K, Kashima H. Magnitude of rater differences in assessment scales for schizophrenia. Journal of Clinical Psychopharmacology. 30: 607-11. PMID 20814326 DOI: 10.1097/Jcp.0B013E3181F0Bae1 |
0.334 |
|
| 2009 |
Suzuki T, Uchida H, Takeuchi H, Nakajima S, Nomura K, Tanabe A, Yagi G, Watanabe K, Kashima H. Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia. Human Psychopharmacology-Clinical and Experimental. 24: 628-638. PMID 19946935 DOI: 10.1002/Hup.1073 |
0.413 |
|
| 2009 |
Nakajima S, Ishida T, Akaishi R, Takahata K, Kitahata R, Uchida H, Suzuki T, Takeuchi H, Nomura K, Nakagawa A, Watanabe K, Kashima H. Impacts of switching antidepressants after successful electroconvulsive therapy on the maintenance of clinical remission in patients with treatment-resistant depression: a chart review. The Journal of Ect. 25: 178-81. PMID 19710625 DOI: 10.1097/Yct.0B013E3181A8E2Ac |
0.318 |
|
| 2009 |
Nakajima S, Suzuki T, Uchida H, Watanabe K, Kashima H. Antipsychotic-induced paroxysmal perceptual alteration in a patient with bipolar disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 33: 160-161. PMID 19032967 DOI: 10.1016/J.Pnpbp.2008.10.021 |
0.302 |
|
| 2008 |
Suzuki T, Uchida H, Nomura K, Takeuchi H, Nakajima S, Tanabe A, Yagi G, Watanabe K, Kashima H. Novel rating scales for schizophrenia — Targeted Inventory on Problems in Schizophrenia (TIP-Sz) and Functional Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz) Schizophrenia Research. 106: 328-336. PMID 18804960 DOI: 10.1016/J.Schres.2008.08.013 |
0.366 |
|
| 2008 |
Takeuchi H, Suzuki T, Uchida H, Nakajima S, Nomura K, Kikuchi T, Manki H, Watanabe K, Kashima H. A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering. Journal of Clinical Psychopharmacology. 28: 540-543. PMID 18794650 DOI: 10.1097/Jcp.0B013E3181842586 |
0.408 |
|
| 2008 |
Suzuki T, Uchida H, Watanabe K, Nakajima S, Nomura K, Takeuchi H, Tanabe A, Yagi G, Kashima H. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. Human Psychopharmacology-Clinical and Experimental. 23: 455-463. PMID 18537222 DOI: 10.1002/Hup.959 |
0.382 |
|
| 2007 |
Nakajima S, Uchida H, Suzuki T, Tomita M, Tsunoda K, Kitta M, Takeuchi H, Nomura K, Watanabe K, Kashima H. An open-label trial of discontinuing benzodiazepines in patients with chronic schizophrenia. Journal of Clinical Psychopharmacology. 27: 401-403. PMID 17632230 DOI: 10.1097/01.Jcp.0000264992.78405.B7 |
0.362 |
|
| Show low-probability matches. |